CorMedix Inc

CRMD · Moat type: REGULIERUNG

MoatScore

8/10

Fair Value

n/a

Margin of Safety

n/a

Rating

BEOBACHTEN

CorMedix develops and markets DefenCath, an antimicrobial catheter lock solution for the prevention of catheter-associated bloodstream infections in dialysis patients, and generates revenue primarily through the sale of this patent-protected, FDA-approved specialty product to dialysis centers in the United States.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.